Despite the PD-1/PD-L1 pathway being recognized as a key checkpoint in the immune response of various cancer types, most patients do not benefit from PD-1/PD-L1 pathway blocking therapies due to primary or acquired resistance (228). Here, CD274 is linked to cancer.